Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Guided Therapeutics (GTHP) Receives Grant to Assist in Commercialization of Cervical Cancer Detection Technology

Guided Therapeutics Inc. is developing a rapid and painless testing platform based on its patented biophotonics technology for the early detection of disease. The National Cancer Institute recently awarded the company $517,000 to fund the final year of a $2.5 million, three-year grant.

The grant provides the company with the necessary resources to help commercialize and bring to market the LuViva(NYSE:TM) Advanced Cervical Scan and Cervical Guide single-patient-use disposable.

LuViva is a non-invasive device that provides immediate detection of cervical disease by scanning the cervix with light, instantly detecting and identifying cancer and pre-cancer. The technology is a stark contrast to Pap or HPV tests, in that it does not require laboratory analysis or a tissue sample.

LuViva is currently under pre-market approval (NYSEARCA:PMA) review by the U.S. Food and Drug Administration.

Since 2011, Guided Therapeutics has been awarded more than $6 million in six consecutive grants from the NCI to support the company’s development of new, pain-free test for detecting cervical disease.

“We view the continuation of the grant as further third-party validation of our technology and it provides additional non-dilutive resources to complete the regulatory process and begin manufacturing,” Mark L. Faupel, Ph.D., president and CEO of Guided Therapeutics stated in the press release.

For more information visit:

Please see disclaimer on the QualityStocks website: